Circulating Cell-Free Tumor DNA: A Promising Liquid Biopsy Method for Cancer Management

 

Circulating Cell-Free Tumor DNA 

All human beings have cell-free DNA circulating in their bloodstream. This cell-free DNA originates from dying anddead cells in the body and gets released into the blood circulation. It consists of short fragments of DNA that measure below 200 base pairs in length. Normally, the proportion of cell-free tumor DNA is very small as compared to the cell-free DNA released from healthy cells. However, in cancer patients, tumor cells are continuously dying and releasing their DNA into the bloodstream. This raises the proportion of circulating tumor DNA (ctDNA). Liquid biopsy methods aim to analyze this ctDNA from a simple blood draw to gain insights into the tumor.

Detecting Mutations from Circulating Cell-Free Tumor DNA

Each tumor harbors genetic mutations that distinguish the cancer cells from healthy cells. Many research studies have shown that ctDNA analysis can be used to detect these tumor-specific mutations in blood samples of cancer patients. Next-generation sequencing technologies allow analysis of large portions of ctDNA to identify mutations that define the patient's tumor. The detection of mutations that arose from the primary tumor or any metastases enables "liquid biopsies" to serve as a non-invasive surrogate of the tumor tissue. ctDNA analysis has been used to detect mutations in genes like KRAS, EGFR, BRAF, and others to help guide cancer treatment decisions.

Monitoring Treatment Response and MRD

By analyzing Circulating Cell-Free Tumor DNA over time, researchers can monitor how a patient responds to various cancer treatments. A decrease in ctDNA levels after initiation of therapy reflects a reduction in the tumor burden. This allows ctDNA to serve as an early predictor of treatment response before anatomical changes occur. Similarly, persistently elevated or increasing ctDNA after treatment suggests inadequate response or emergence of resistance. ctDNA analysis provides a very early signal towards such treatment failures. It also enables detection of minimal residual disease or MRD after curative intent therapies by picking up remaining tumor DNA even if imaging cannot detect any remaining tumor mass.

Understanding Resistance Mechanisms

When treatments stop working for cancer patients, circulating cell-free tumor DNA analysis can help uncover the genetic reasons behind acquired resistance. Repeated analysis ofctDNA over the course of therapy can identifynew mutations that emerge only after exposure to certain drugs. Such "resistance mutations" provide crucial insights into why tumors adapt to evade specific treatments. For example, new EGFR mutations like T790M explain resistance to first-generation EGFR inhibitors in lung cancer. Targeting these resistance mutations with newer drugs rationalizes further treatment strategies. ctDNA analysis thus serves as a powerful tool for real-time surveillance of resistance evolution.

Guiding Treatment with Liquid Biopsies

Armed with tumor mutation profiles from ctDNA analysis, oncologists can choose targeted therapies that attack the specific molecular weaknesses of a patient's cancer. ctDNA findings may guide decisions towards certain chemotherapy drugs, immunotherapies, hormone therapies or kinase inhibitors depending on the detected mutations. Combined with information about resistance mutations, ctDNA serves as a truly non-invasive genomic guide for personalizing cancer management strategies based on longitudinal tumor evolution. It reduces reliance on invasive tumor biopsies and enables regular monitoring throughout all lines of treatment.

Clinical Validation of ctDNA Testing

While exciting in theory, circulating cell-free tumor DNA analysis needed validation through rigorous clinical studies before being accepted into practice. Pivotal trials have now definitively shown that ctDNA tests can successfully identify actionable tumor mutations and track treatment responses in various cancers. For example, the prospectiveblood prognosis in lung cancer (B-PILOT) study validatedctDNA testing for guiding EGFR-TKI therapies in lung cancer. Similarly, trials in colorectal cancer demonstrated high accuracy of ctDNA for detecting RAS mutations, which determine eligibility for anti-EGFR monoclonal antibodies. As more and more evidence accumulates, medical guidelines now recommend use of ctDNAtests in certain clinical scenarios to complement standard tumor assessment.

Future Applications and Technical Advances

Going forward, circulating cell-free tumor DNA analysis seeks to address several remaining challenges and expand its clinical utility further:

- Earlier detection of cancer: ctDNA may enable screening of at-risk populations before anatomical signs emerge by detecting tumor-released DNA at an even earlier, curable stage than conventional methods. This requires extreme sensitivity to detect vanishingly small amounts of ctDNA.

- Guiding surgery: Monitoring pre- and post-surgical ctDNA levels may allow assessing completeness of resection and guide decisions on adjuvant treatments. Decreasing ctDNA post-surgery would reflect effective removal of all detectable disease.

- Personalized monitoring: Serial ctDNA tests every few months may enable lifelong personalized surveillance of cancer recurrence risk based on individual tumor biology over time.

- Multi-cancer detection: Recent technical advances enable simultaneous analysis of ctDNA from different organs, allowing detection of multiple co-occurring tumors from a single blood draw.

- Improved assays: Continuous development aims to simplify ctDNA extraction, reduce cost barriers and deliver results more quickly and conveniently without need for specialized laboratories.

Circulating cell-free tumor DNA with ongoing validation and technical progress, it aims to overcome limitations of tissue biopsies and imaging for optimally guiding personalized cancer care throughout a patient's journey based on real-time tumor monitoring.

 

Get more insights on Circulating Cell-Free Tumor DNA

 

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)